Aliada Therapeutics is a biotech firm pioneering therapies that target the blood-brain barrier (BBB) to enhance treatments for neurological and psychiatric disorders. Using a platform designed to increase biologic delivery across the BBB, Aliada aims to overcome the limitations of current brain disease therapies by improving drug reach and efficacy. Guided by a team with extensive experience in neuroscience and biologics, along with insights from key academic and industry leaders, Aliada’s goal is to make impactful strides in central nervous system disease treatment.